Ibrutinib: from bench side to clinical implications
| Autor: | Andrea Ravelli, Roberto Tessari, Daniele Generali, Milo Gatti, Francesco Lanza, Francesca Tasca, Valeria Gianardi, Alessandra Maestro, Walter Fiore, Giampaolo Tirone, Francesco Scaglione, Camilla Grumi, Ludovica Piazzoni, Davide Grisafi |
|---|---|
| Přispěvatelé: | Grisafi D., Maestro A., Grumi C., Piazzoni L., Tirone G., Fiore W., Tessari R., Gianardi V., Gatti M., Tasca F., Generali D., Ravelli A., Lanza F., Scaglione F., Grisafi, Davide, Maestro, Alessandra, Grumi, Camilla, Piazzoni, Ludovica, Tirone, Giampaolo, Fiore, Walter, Tessari, Roberto, Gianardi, Valeria, Gatti, Milo, Tasca, Francesca, Generali, Daniele, Ravelli, Andrea, Lanza, Francesco, Scaglione, Francesco |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Cancer Research
Biomedical Research Lymphoma Chronic lymphocytic leukemia Follicular lymphoma Antineoplastic Agent chemistry.chemical_compound Piperidines immune system diseases hemic and lymphatic diseases Bruton’s tyrosine kinase Ibrutinib Mantle cell lymphoma Non-Hodgkin lymphoma Humans Leukemia Lymphocytic Chronic B-Cell Antineoplastic Agents Pyrazoles Pyrimidines B lymphocytes immunophenotype Medicine Chronic Leukemia biology Waldenstrom macroglobulinemia General Medicine Hematology Oncology BCL10 Lymphocytic immunophenotype Human B-cell receptor NO Piperidine Bruton's tyrosine kinase business.industry Adenine B-Cell medicine.disease Pyrimidines chemistry Immunology Pyrazole biology.protein business Diffuse large B-cell lymphoma B lymphocytes |
| Popis: | The activation of the B cell receptor (BCR) is nowadays known to play a primary role in the etiopathogenesis of a multitude of B cell malignancies, being one of the main factors responsible for the enhanced proliferation and survival of transformed cells. Thanks to the characterization and continuous discovery of the pathways driving B cell proliferation in consequence to BCR activation, it has been possible to develop a small molecule inhibitor specifically antagonizing the Bruton's tyrosine kinase (BTK), an enzyme located in an early strategic position within the whole pathway. Ibrutinib, formerly PCI-32765, is a first in class, potent, specific, irreversible and relatively safe BTK inhibitor, demonstrating so far an impressive efficacy in the treatment of chronic lymphocytic leukemia, diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma (MCL), Waldenström macroglobulinemia and multiple myeloma. This review will summarize the most important pharmacological evidences available as of today and will take in consideration the latest findings regarding the mechanism of action of ibrutinib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|